Patients this decision actually applies to

Not every patient facing a knee replacement referral is in the same situation — and whether ChondroFiller injection is worth exploring depends almost entirely on what the imaging shows, not on age.

Knee replacement is the right answer when arthritis has reached the point of bone-on-bone wear across the whole joint. At that stage, the cartilage surface is gone and structural loss is irreversible; no injectable treatment changes that picture, and a surgeon's referral reflects sound clinical judgement.

ChondroFiller is a different kind of treatment for a different kind of problem. It is a joint-preservation injectable collagen scaffold — placed under ultrasound guidance — for patients who have a contained area of cartilage damage alongside reasonably healthy surrounding tissue. The scaffold works by recruiting the patient's own progenitor cells to support endogenous repair at the affected site. It is not indicated for globally worn joints.

The patients for whom this choice genuinely arises tend to be in their 60s or 70s: active individuals who have received a surgical referral, but whose joint, on closer imaging review, shows focal rather than end-stage wear. ChondroFiller carries no formal upper age ceiling — suitability turns on defect characteristics and the condition of the surrounding cartilage, not on age alone.

The starting point for any decision is a specialist assessment with up-to-date imaging — MRI or weight-bearing X-ray — to establish whether a focal defect or generalised arthritis is the dominant finding. That distinction determines which pathway is clinically appropriate.

How the injectable collagen scaffold works

ChondroFiller is a CE-marked Class III medical device — a purified, acellular Type I collagen solution administered as an outpatient, image-guided injection. Once placed into the cartilage defect, the solution self-gels within minutes, conforming to the defect's contours and bonding to the surrounding tissue. No incisions or theatre time are involved.

The clinical term for the mechanism is acellular matrix-induced chondrogenesis: rather than delivering pre-grown tissue or live cells, the scaffold acts as a biological template that recruits the patient's own repair cells. Progenitor cells from the synovium and subchondral bone migrate into the gelled matrix, mature into chondrocyte-like cells, and begin depositing cartilage matrix at the defect site. The repair is driven entirely by the patient's own biology; the device provides the structural conditions for that process to occur.

Over approximately six to twelve months the collagen scaffold is gradually resorbed as the body lays down new tissue in its place. Imaging studies show that this maturation is progressive across that window rather than complete at a fixed point. The mechanism depends on viable surrounding cartilage to supply the migrating cells — which is why, as imaging at assessment establishes, the treatment is suited to focal defects with a healthy biological neighbourhood rather than to joints where surrounding tissue is itself exhausted.

The scaffold supports the body's own repair processes; it does not in itself regrow cartilage. The extent of the tissue response reflects the patient's own regenerative capacity at the site.

What the clinical outcomes data shows

Interpreting any outcome score requires a reference point. For the International Knee Documentation Committee (IKDC) functional scale, the established minimum clinically important difference — the smallest change a patient would genuinely notice — is 16.7 points. Improvements below that threshold may be statistically detectable but are unlikely to translate into meaningful day-to-day function.

Across four independent knee studies, mean IKDC improvements following ChondroFiller injection ranged from approximately 30 points at 12 months — roughly twice the MCID threshold. The most durable dataset available is the Jerosch et al. prospective post-market follow-up study, which recorded a mean improvement of 32.4 points sustained and slightly increased at 36 months, with patients reaching a mean final IKDC score of 80. A score in that range corresponds to good-to-normal knee function, suggesting the gains reported at one year were not simply temporary relief that faded thereafter.

Structural MRI data using the MOCART scoring system provides a separate line of corroboration. MOCART quantifies defect fill and tissue integration on a 0–100 scale; scores in the Jerosch series progressed from 65.3 at four weeks to between 81.6 and 84.3 at one year — consistent with the six-to-twelve-month maturation window described by the biological mechanism. Scores above 80 indicate more than 80% defect fill and good integration with surrounding native tissue.

In terms of real-world volume, over 19,000 ChondroFiller procedures have been performed globally, providing a meaningful denominator beyond the trial populations in published studies.

The evidence does carry limitations that should be stated plainly. Published studies have been manufacturer-sponsored or conducted by investigators linked to the developing centre; no independent randomised controlled trial comparing ChondroFiller with total knee replacement has been published to date, and independent long-term data beyond three years remain limited. These are factual gaps in the evidence base, not reasons to set aside the existing data — but they are relevant to patients weighing this option and worth raising at consultation.

How ChondroFiller compares with total knee replacement

The practical differences between the two options are substantial. Total knee replacement is a major operation — performed under general or spinal anaesthesia, requiring hospital admission and typically several months of structured rehabilitation before patients recover full function. ChondroFiller is an outpatient, image-guided injection appointment: no theatre, no overnight stay, and no surgical wound to heal.

Structurally, the two procedures address different problems. Knee replacement removes and resurfaces all of the joint's weight-bearing surfaces, replacing native cartilage and bone with metal and polyethylene implants. ChondroFiller leaves the joint intact and treats the focal area — the native anatomy is preserved, and any repair is driven by the patient's own biology within the existing joint architecture.

The question of whether ChondroFiller represents genuine regeneration or simply a period of relief before inevitable surgery is settled by the mechanism and the available data together. The scaffold is designed to recruit the patient's own repair cells at the defect site; as the Jerosch et al. three-year post-market follow-up data show, mean functional gains of around 32 points on the IKDC scale were sustained at 36 months rather than declining back toward baseline — a pattern more consistent with structural repair than temporary symptom masking. Independent long-term data beyond three years remain limited, and no randomised controlled trial has yet compared ChondroFiller directly with total knee replacement, so confidence in the durability claim should be appropriately measured.

Where both options have entered the conversation, specialist assessment with current MRI determines whether the defect pattern fits the focal-repair pathway or whether joint involvement is too extensive for preservation to remain viable.

When Liquid Cartilage adds your own cells to the scaffold

For focal defects that are too large or structurally complex for the scaffold injection alone, a second pathway is available: a combination approach that pairs the same ChondroFiller collagen scaffold with the patient's own autologous cells — typically derived from bone marrow or adipose tissue — to augment the repair signal at the defect site.

The cell component requires a preparatory harvesting step at the same outpatient visit before the injection is administered. This is a cell-preparation procedure, not a surgical operation: there is no theatre admission, no incision of clinical consequence, and no general anaesthetic. The harvested cells are processed and delivered alongside the scaffold as part of a single in-clinic appointment.

Both pathways are self-funded and sit outside NHS and private medical insurance coverage — a practical consideration worth confirming before pursuing a referral. Guide costs for these treatments typically run into the thousands of pounds, with the combination cell-augmented pathway costing meaningfully more than the scaffold injection alone; exact figures vary by provider and should be confirmed directly with the treating specialist.

Neither pathway is indicated for end-stage, bone-on-bone disease. The combination approach extends the eligible population to patients with larger focal defects, but it does not extend the indication to joints where viable cartilage tissue is no longer present to support the repair process.

Getting assessed and finding a specialist

The practical starting point is a specialist consultation with current imaging in hand. If a recent MRI exists, bring it to that appointment; if not, one is usually arranged as part of the initial assessment. The scan reveals whether cartilage loss is focal and bounded or diffuse and end-stage — a distinction that drives everything that follows.

A few questions are worth raising at that review:

• Is the damage limited to one defined area, or has it spread across the joint surfaces?
• Would the injectable scaffold alone suit my defect pattern, or is the combination cell-augmented pathway more appropriate?
• What does the follow-up imaging schedule look like, and at what point would the approach be reconsidered?

Patients already on a waiting list for knee replacement can request a specialist second opinion at any point before proceeding. Whether imaging confirms focal or generalised disease is the single most consequential piece of information — it determines whether joint preservation remains a realistic option, and it is a question that deserves a clear answer before any surgical commitment is made.

Search MSK lists cartilage preservation specialists across the UK who offer ChondroFiller injection and cartilage assessment, searchable by region and specialty.